Company news
Annexon, Inc. (NASDAQ:ANNX) news
Every Annexon, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
August 12, 2026
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 ...
August 12, 2026
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors
August 10, 2026
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
July 30, 2026
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patie...
July 14, 2026
Annexon to Participate in Upcoming June Investor Conferences
May 27, 2026
Annexon Reports Inducement Grants to New Employees under Nasdaq Listing Rule 5635(4)
May 19, 2026
Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
May 7, 2026
Annexon to Present at the Bank of America Securities Health Care Conference 2026
May 6, 2026
Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
March 30, 2026
Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference
February 24, 2026
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy
February 17, 2026
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrati...
January 12, 2026
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome
January 8, 2026
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 7, 2026
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
December 16, 2025
Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds o...
November 14, 2025
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
November 12, 2025
Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
November 12, 2025
Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
November 10, 2025
Annexon Biosciences to Participate in Upcoming September Investor Conferences
August 27, 2025
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
August 14, 2025
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Dege...
August 7, 2025
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macula...
July 24, 2025
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in D...
June 18, 2025
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference
May 29, 2025
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve So...
May 19, 2025
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
May 12, 2025
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Sy...
May 9, 2025
Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress
May 7, 2025
Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Cam...
April 8, 2025
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neuro...
April 3, 2025
Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones
March 3, 2025
Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference
February 26, 2025
Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society...
February 13, 2025
Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year
January 13, 2025
Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones
January 10, 2025
Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 7, 2025
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg)...
December 16, 2024
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOO...
December 5, 2024
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
November 14, 2024
Annexon Biosciences to Present at the Jefferies London Healthcare Conference
November 13, 2024
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophtha...
October 21, 2024
Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology ...
October 15, 2024
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Mee...
September 9, 2024
Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targ...
September 3, 2024
Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
August 12, 2024
Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy
August 5, 2024